Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 426Active not recruiting 135Terminated 125Recruiting 106Unknown 63Withdrawn 35Not yet recruiting 21Enrolling by invitation 3Suspended 2

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 2Smoldering Multiple Myeloma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1

Interventions

Cisplatin 9Standard of Care 6Educational Status 6Nivolumab 5Interviews as Topic 5Carboplatin 5Radiotherapy 4Paclitaxel 4Oxaliplatin 4Fluorodeoxyglucose F18 4Dexamethasone 4pembrolizumab 3camrelizumab 3Practice Guidelines as Topic 3Patient Navigation 3Methods 3Magnetic Resonance Spectroscopy 3Magnetic Resonance Imaging 3Lenalidomide 3Fluorouracil 3Exercise 3Early Intervention, Educational 3Drug Therapy 3Cytarabine 3130-nm albumin-bound paclitaxel 3venetoclax 2toripalimab 2tislelizumab 2sacituzumab govitecan 2lenvatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Enrolling by invitation × Interventional × Lenalidomide × Clear all
NCT07210047 2025-10-07

Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients

HuniLife Biotechnology, Inc.

Phase 1/2 Enrolling by invitation
21 enrolled
Plasma cell

Multiple Myeloma

NCT06762431 2025-01-07

VTB-CLL002

Vitebsk Regional Clinical Cancer Centre

Phase 1/2 Enrolling by invitation
60 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03815279 2019-08-16

iStopMM

Landspitali University Hospital

Phase 2 Enrolling by invitation
80 enrolled
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡